A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events

A 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidemi, Sawada, Koji, Hasebe, Takumu, Nakajima, Shunsuke, Sawada, Jun, Takiyama, Yuri, Takiyama, Yumi, Okumura, Toshikatsu, Fujiya, Mikihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790772/
https://www.ncbi.nlm.nih.gov/pubmed/35491133
http://dx.doi.org/10.2169/internalmedicine.9393-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790772/
https://www.ncbi.nlm.nih.gov/pubmed/35491133
http://dx.doi.org/10.2169/internalmedicine.9393-22

Ejemplares similares